Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence that includes FP-RMS, harboring the fusion oncoprotein PAX3/7-FOXO1 and FN-RMS, often mutant in the RAS pathway. Risk stratifications of RMS patients determine different prognostic groups and related therapeutic treatment. Current multimodal therapeutic strategies involve surgery, chemotherapy (CHT) and radiotherapy (RT), but despite the deeper knowledge of response mechanisms underpinning CHT treatment and the technological improvements that characterize RT, local failures and recurrence frequently occur. This review sums up the RMS classification and the management of RMS patients, with special attention to RT treatment and possible radiosensitizing strategies for RMS tumors. Indeed, RMS radioresistance is a clinical problem and further studies aimed at dissecting radioresistant molecular mechanisms are needed to identify specific targets to hit, thus improving RT-induced cytotoxicity.

Pomella, S., Porrazzo, A., Cassandri, M., Camero, S., Codenotti, S., Milazzo, L., et al. (2022). Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(21), 1-24 [10.3390/ijms232113281].

Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma

Pomella, Silvia;Cassandri, Matteo;Barillari, Giovanni;
2022-10-31

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence that includes FP-RMS, harboring the fusion oncoprotein PAX3/7-FOXO1 and FN-RMS, often mutant in the RAS pathway. Risk stratifications of RMS patients determine different prognostic groups and related therapeutic treatment. Current multimodal therapeutic strategies involve surgery, chemotherapy (CHT) and radiotherapy (RT), but despite the deeper knowledge of response mechanisms underpinning CHT treatment and the technological improvements that characterize RT, local failures and recurrence frequently occur. This review sums up the RMS classification and the management of RMS patients, with special attention to RT treatment and possible radiosensitizing strategies for RMS tumors. Indeed, RMS radioresistance is a clinical problem and further studies aimed at dissecting radioresistant molecular mechanisms are needed to identify specific targets to hit, thus improving RT-induced cytotoxicity.
31-ott-2022
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/05 - PATOLOGIA CLINICA
English
radiation therapy
radioresistance
radiosensitizers
radiotherapy
rhabdomyosarcoma
Pomella, S., Porrazzo, A., Cassandri, M., Camero, S., Codenotti, S., Milazzo, L., et al. (2022). Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(21), 1-24 [10.3390/ijms232113281].
Pomella, S; Porrazzo, A; Cassandri, M; Camero, S; Codenotti, S; Milazzo, L; Vulcano, F; Barillari, G; Cenci, G; Marchese, C; Fanzani, A; Megiorni, F; ...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
ijms-23-13281-v2.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 1.19 MB
Formato Adobe PDF
1.19 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/311723
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact